e-learning
resources
European Respiratory Review
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The impact of personalised therapies on respiratory medicine
J. Stuart Elborn
Source:
Eur Respir Rev 2013; 22: 72-74
Journal Issue:
March 2013 - 22 (127)
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Stuart Elborn. The impact of personalised therapies on respiratory medicine. Eur Respir Rev 2013; 22: 72-74
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
The future of personalised medicine in COPD
Source: International Congress 2016 – Endotyping: the means to personalised medicine in lung disease
Year: 2016
Personalised medicine in asthma: from curative to preventive medicine
Source: Eur Respir Rev 2017; 26: 160010
Year: 2017
What is evidence-based medicine?
Source: Annual Congress 2006 - PG16 - The use of evidence-based medicine and practice for the clinician (jointly organised with the ACCP)
Year: 2006
The clinical benefit of personalised medicine in lung cancer
Source: International Congress 2014 – Understanding the benefit of current personalised medicine platforms
Year: 2014
A personalised medicine approach to ICS use in COPD
Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care
Year: 2019
Personalised medicine for cystic fibrosis: treating the basic defect
Source: Eur Respir Rev 2013; 22: 3-5
Year: 2013
Biomarkers and personalised medicine for asthma
Source: Eur Respir J, 53 (1) 1802094; 10.1183/13993003.02094-2018
Year: 2019
Advanced cell culture techniques and personalised medicine for cystic fibrosis
Source: International Congress 2015 – Respiratory research in the Netherlands
Year: 2015
Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis
Source: Eur Respir J, 51 (6) 1702457; 10.1183/13993003.02457-2017
Year: 2018
Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy
Source: Breathe, 17 (4) 210112; 10.1183/20734735.0112-2021
Year: 2021
Diagnosing asthma in the era of personalised medicine: biology, physiology and imaging
Source: Virtual Congress 2021 – Precision medicine in asthma and COPD
Year: 2021
In the era of personalized medicine, what are the current unmet needs in asthma?
Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now?
Year: 2019
Current insights and potential benefits for effective teaching and learning in respiratory medicine
Source: Breathe 2012; 9: 15-24
Year: 2012
Is cystic fibrosis the hemi-neglected part of respiratory medicine?
Source: Virtual Congress 2021 – CCC Thoracic oncology
Year: 2021
Palliative medicine services for those with chronic lung disease
Source: Annual Congress 2008 - Integrated care and long-term strategies
Year: 2008
Personalised medicine in interstitial lung diseases
Source: Eur Respir Rev, 27 (148) 170117; 10.1183/16000617.0117-2017
Year: 2018
Genomically-guided therapies: a new era for cystic fibrosis
Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept